Mild Cognitive Impairment

Severe menopause symptoms, such as hot flashes and depressive mood, were associated with mild cognitive impairment for postmenopausal women, researchers reported in Menopause.

PHILADELPHIA — A computerized cognitive battery was effective in detecting cognitive impairment and amyloid presence in preclinical Alzheimer’s disease, James E. Galvin, MD, MPH, said in this Healio Video Perspective.

PHILADELPHIA — In a small cohort of individuals with mild cognitive impairment or dementia, sleep disruption was associated with weekly agitation level, according to a presenter.

PHILADELPHIA — Script generation task performance may be a cost-effective, reliable tool to assess early cognitive impairment in older adults, according to a poster presentation.

PHILADELPHIA — Utilization of a specialized blood test to detect Alzheimer’s-related pathology led to higher diagnostic accuracy compared to health care professionals’ identification, data show.

The FDA approved Kisunla for adults with early symptomatic Alzheimer’s disease, including those with mild cognitive impairment and mild dementia with confirmed amyloid pathology.

A self-administered assessment tool was effective in identifying cognitive impairment vs. routine care in primary care settings, according to results recently published in Frontiers in Medicine.

An FDA advisory panel on Monday voted in favor of donanemab as a treatment for early symptomatic Alzheimer’s disease.

The FDA’s approval of Leqembi in July 2023 triggered a wave of discussion in the medical community on how to prescribe and properly administer the amyloid-targeting antibody to treat those diagnosed with Alzheimer’s disease.

Eisai and Biogen have submitted a supplemental biologics license application to the FDA for monthly IV maintenance dosing of Leqembi to treat Alzheimer’s disease in patients with mild cognitive impairment or mild dementia.